Interestingly, EVI-1high AML cells are sensitized to LSD1 inhibition by venetoclax (122), suggesting that immature AML cases, which have their origin in the HSC or MPP, can be sensitized for anti-LSD1-induced apoptosis by therapeutic targeting of BCL2. The gene discussed is KDM1A; the disease is acute myeloid leukemia.